Skip to main content
main-content

The independent medical news service

26-01-2022 | Oncology | News | Article

Radiotherapy futile add-on to durvalumab–tremelimumab in refractory NSCLC

Adding low-dose or hypofractionated radiotherapy to durvalumab plus tremelimumab offers no significant benefit to people with non-small-cell lung cancer that is resistant to PD-1 or PD-L1 inhibition, US study findings indicate.

24-01-2022 | Oncology | News | Article

Cutaneous irAEs linked to improved survival following ICI therapy

Cutaneous immune-related adverse events are associated with a reduced risk for death among cancer patients with immune checkpoint inhibitors, research suggests.

20-01-2022 | Oncology | Highlight | Article

Sugemalimab shows promise for locally advanced, metastatic NSCLC

The PD-L1 inhibitor sugemalimab has shown potential both as a consolidation treatment option for inoperable, locally advanced non-small-cell lung cancer as well as in combination with chemotherapy for the first-line treatment of metastatic disease.

18-01-2022 | Oncology | News | Article

Reassurance on radiotherapy use prior to ICI initiation

Treatment with immune checkpoint inhibitors within 90 days of radiotherapy does not lead to a “meaningful increase” in rates of serious adverse events, say researchers who conducted a pooled analysis of US FDA registry data.

17-01-2022 | Oncology | News | Article

BMI may be key to unlocking metformin NSCLC benefit

A post-hoc analysis of a randomized trial points to the benefit of adding metformin to an EGFR–tyrosine kinase inhibitor in advanced non-small-cell lung cancer patients with a BMI of at least 24 kg/m2.

13-01-2022 | Oncology | News | Article

Meta-analysis confirms benefit of quitting smoking at lung cancer diagnosis

Quitting smoking around the time of receiving a lung cancer diagnosis is associated with significantly improved overall survival than continuing smoking, shows a meta-analysis published in the Journal of Thoracic Oncology.

Image Credits